These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37826938)

  • 41. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
    Wu W; Ke M; Ye L; Lin C
    Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
    Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
    Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
    Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
    Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling.
    Li S; Yu Y; Bian X; Yao L; Li M; Lou YR; Yuan J; Lin HS; Liu L; Han B; Xiang X
    Arch Toxicol; 2021 May; 95(5):1683-1701. PubMed ID: 33713150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
    Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
    Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
    [No Abstract]   [Full Text] [Related]  

  • 46. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.
    Kinvig H; Cottura N; Lloyd A; Frivold C; Mistilis J; Jarrahian C; Siccardi M
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):855-868. PubMed ID: 36178586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
    Bussing D; K Shah D
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
    Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
    Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.
    Huang W; Nakano M; Sager J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2017 Nov; 45(11):1156-1165. PubMed ID: 28860113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics.
    Parmar KR; Lukka PB; Wagh S; Temrikar ZH; Liu J; Lee RE; Braunstein M; Hickey AJ; Robertson GT; Gonzalez-Juarrero M; Edginton A; Meibohm B
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PBPK Modeling as an Alternative Method of Interspecies Extrapolation that Reduces the Use of Animals: A Systematic Review.
    Lancheros Porras KD; Alves IA; Novoa DMA
    Curr Med Chem; 2024; 31(1):102-126. PubMed ID: 37031391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: a physiologically based mathematical model.
    Clarke DO; Elswick BA; Welsch F; Conolly RB
    Toxicol Appl Pharmacol; 1993 Aug; 121(2):239-52. PubMed ID: 8346541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling.
    Huang W; Isoherranen N
    J Pharmacol Exp Ther; 2020 Jan; 372(1):30-45. PubMed ID: 31604807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment.
    Dubbelboer IR; Sjögren E; Lennernäs H
    AAPS J; 2018 Aug; 20(6):96. PubMed ID: 30167825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions.
    Lee W; Kim MS; Kim J; Aoki Y; Sugiyama Y
    Drug Metab Dispos; 2023 Sep; 51(9):1145-1156. PubMed ID: 36914276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.